NCT00058019View on ClinicalTrials.gov

Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Anaplastic Large Cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma
Interventions
DRUG

ixabepilone

Given IV

Trial Locations (2)

60637

University of Chicago, Chicago

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00058019 - Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter